163 related articles for article (PubMed ID: 25936211)
1. Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19.
Fietta P; Costa E; Delsante G
Theor Biol Forum; 2014; 107(1-2):13-45. PubMed ID: 25936211
[TBL] [Abstract][Full Text] [Related]
2. Interleukins (ILs), a fascinating family of cytokines. Part II: ILs from IL-20 to IL-38.
Fietta P; Costa E; Delsante G
Theor Biol Forum; 2015; 108(1-2):19-40. PubMed ID: 27167908
[TBL] [Abstract][Full Text] [Related]
3. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases.
Akdis M; Burgler S; Crameri R; Eiwegger T; Fujita H; Gomez E; Klunker S; Meyer N; O'Mahony L; Palomares O; Rhyner C; Ouaked N; Schaffartzik A; Van De Veen W; Zeller S; Zimmermann M; Akdis CA
J Allergy Clin Immunol; 2011 Mar; 127(3):701-21.e1-70. PubMed ID: 21377040
[TBL] [Abstract][Full Text] [Related]
4. Natural products modulating interleukins and other inflammatory mediators in tumor-bearing animals: A systematic review.
Gandhi GR; Antony PJ; Lana MJMP; da Silva BFX; Oliveira RV; Jothi G; Hariharan G; Mohana T; Gan RY; Gurgel RQ; Cipolotti R; Quintans LJ
Phytomedicine; 2022 Jun; 100():154038. PubMed ID: 35358934
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death.
Heinhuis B; Netea MG; van den Berg WB; Dinarello CA; Joosten LA
Cytokine; 2012 Nov; 60(2):321-7. PubMed ID: 22878344
[TBL] [Abstract][Full Text] [Related]
6. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
[TBL] [Abstract][Full Text] [Related]
7. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators.
Harizi H; Gualde N
Cell Mol Immunol; 2006 Aug; 3(4):271-7. PubMed ID: 16978535
[TBL] [Abstract][Full Text] [Related]
8. IL-33: a sheep in wolf's clothing?
Gadina M; Jefferies CA
Sci STKE; 2007 Jun; 2007(390):pe31. PubMed ID: 17565120
[TBL] [Abstract][Full Text] [Related]
9. IL-17 and IL-22: siblings, not twins.
Eyerich S; Eyerich K; Cavani A; Schmidt-Weber C
Trends Immunol; 2010 Sep; 31(9):354-61. PubMed ID: 20691634
[TBL] [Abstract][Full Text] [Related]
10. IL-22 and inflammation: leukin' through a glass onion.
Zenewicz LA; Flavell RA
Eur J Immunol; 2008 Dec; 38(12):3265-8. PubMed ID: 19016525
[TBL] [Abstract][Full Text] [Related]
11. Th17 cytokines and their emerging roles in inflammation and autoimmunity.
Fouser LA; Wright JF; Dunussi-Joannopoulos K; Collins M
Immunol Rev; 2008 Dec; 226():87-102. PubMed ID: 19161418
[TBL] [Abstract][Full Text] [Related]
12. Evolutionary divergence and functions of the human interleukin (IL) gene family.
Brocker C; Thompson D; Matsumoto A; Nebert DW; Vasiliou V
Hum Genomics; 2010 Oct; 5(1):30-55. PubMed ID: 21106488
[TBL] [Abstract][Full Text] [Related]
13. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
14. Targeting fusion proteins of the interleukin family: A promising new strategy for the treatment of autoinflammatory diseases.
Zhao Y; Wang H; Jin L; Zhang Z; Liu L; Zhou M; Zhang X; Zhang L
Eur J Pharm Sci; 2024 Jan; 192():106647. PubMed ID: 37984595
[TBL] [Abstract][Full Text] [Related]
15. Insights into the role of IL-32 in cancer.
Sloot YJE; Smit JW; Joosten LAB; Netea-Maier RT
Semin Immunol; 2018 Aug; 38():24-32. PubMed ID: 29747940
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells.
Pollheimer J; Bodin J; Sundnes O; Edelmann RJ; Skånland SS; Sponheim J; Brox MJ; Sundlisaeter E; Loos T; Vatn M; Kasprzycka M; Wang J; Küchler AM; Taskén K; Haraldsen G; Hol J
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):e47-55. PubMed ID: 23162017
[TBL] [Abstract][Full Text] [Related]
17. Interleukin role in the regulation of endothelial cell pathological activation.
Carbone ML; Failla CM
Vasc Biol; 2021; 3(1):R96-R105. PubMed ID: 34870094
[TBL] [Abstract][Full Text] [Related]
18. The growing spectrum of anti-inflammatory interleukins and their potential roles in the development of sepsis.
Zhao HQ; Li WM; Lu ZQ; Sheng ZY; Yao YM
J Interferon Cytokine Res; 2015 Apr; 35(4):242-51. PubMed ID: 25517926
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1.
Turner-Brannen E; Choi KY; Arsenault R; El-Gabalawy H; Napper S; Mookherjee N
J Immunol; 2011 Jun; 186(12):7127-35. PubMed ID: 21602493
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-32: An endogenous danger signal or master regulator of intracellular pathogen infections-Focus on leishmaniases.
Dos Santos JC; Damen MSMA; Joosten LAB; Ribeiro-Dias F
Semin Immunol; 2018 Aug; 38():15-23. PubMed ID: 29551246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
